Showing results (41-50 of 56) with videos related to
Sort By:
Pageof 6
Bioorganic & Medicinal Chemistry Letters|March 17, 2009
Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorsRonghui Lin, Sigmond G Johnson, Peter J Connolly, et al.Bioorganic & Medicinal Chemistry Letters|May 29, 2007
Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agentsRonghui Lin, Peter J Connolly, Yanhua Lu, et al.Bioorganic & Medicinal Chemistry Letters|June 13, 2020
The discovery of azetidine-piperazine di-amides as potent, selective and reversible monoacylglycerol lipase (MAGL) inhibitorsBin Zhu, Peter J Connolly, Yue-Mei Zhang, et al.Bioorganic & Medicinal Chemistry Letters|July 26, 2008
4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitorsGuozhang Xu, Marta C Abad, Peter J Connolly, et al.Bioorganic & Medicinal Chemistry Letters|April 20, 2005
3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluationRonghui Lin, Yanhua Lu, Steven K Wetter, et al.Bioorganic & Medicinal Chemistry Letters|May 8, 2007
4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluationTerry V Hughes, Stuart L Emanuel, Amanda K Beck, et al.Journal of Medicinal Chemistry|January 20, 2021
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)Zhuming Zhang, Peter J Connolly, Heng Keang Lim, et al.Journal of Medicinal Chemistry|July 22, 2005
Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitorsGee-Hong Kuo, Catherine Prouty, Aihua Wang, et al.Molecular Pharmacology|November 3, 2007
Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumorsStuart L Emanuel, Terry V Hughes, Mary Adams, et al.Molecular Cancer Therapeutics|March 2, 2021
Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate CancerJonathan R Branch, Tammy L Bush, Vineet Pande, et al.Pageof 6